Collectively, our findings suggest that RACK1 facilitates breast cancer progression by competitively inhibiting β-catenin binding to PSMD2, increasing β-catenin stability, and promoting WNT pathway activation (Fig. 8). Here, PSMD2 is linked to breast cancer.